1379323-52-0

Basic information

• Product Name: 2-(bromomethyl)-3-chlorobenzaldehyde
• Synonyms: 2-(bromomethyl)-3-chlorobenzaldehyde
• CAS NO: 1379323-52-0
• Molecular Weight: 233.492
• Mol File: 1379323-52-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(bromomethyl)-3-chlorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(bromomethyl)-3-chlorobenzaldehyde(1379323-52-0)
• EPA Substance Registry System: 2-(bromomethyl)-3-chlorobenzaldehyde(1379323-52-0)

Safety Data

• Hazardous Substances Data: 1379323-52-0(Hazardous Substances Data)

Upstream product

• 7499-08-3 3-chloro-2-methylbenzoic acid 
• 99586-84-2 methyl 2-methyl-3-chlorobenzoate 
• 188187-03-3 2-bromomethyl-3-chloro-benzoic acid methyl ester 
• 1379313-10-6 [2-(bromomethyl)-3-chlorophenyl]methanol 
• 77533-18-7 2-(bromomethyl)-3-chlorobenzonitrile 

Downstream Products

• 1418202-49-9 8-chloro-2-phenyl-1,2-dihydrophthalazine 
• 1449754-12-4 C₂₁H₂₈ClF₂N₃O₃ 
• 1427309-44-1 tert-butyl 4-[(3S,4R)-3-[2-(tert-butoxy)-2-oxoethyl]-1-{[2-chloro-6-(difluoromethyl)phenyl]methyl}-4-methylpyrrolidin-3-amido]piperidine-1-carboxylate 
• 1427058-40-9 2-[(3S,4R)-1-{[2-chloro-6-(difluoromethyl)phenyl]methyl}-3-{[1-(cyclohex-1-en-1-ylmethyl)piperidin-4-yl]carbamoyl}-4-methylpyrrolidin-3-yl]acetic acid 
• 1427309-42-9 tert-butyl 2-[(3S,4R)-1-{[2-chloro-6-(difluoromethyl)phenyl]methyl}-3-[(1-hexylpiperidin-4-yl)carbamoyl]-4-methylpyrrolidin-3-yl]acetate 
• 1427058-75-0 2-(bromomethyl)-1-chloro-3-(difluoromethyl)benzene 

Relevant articles and documents

PYRROLIDINE-3-YLACETIC ACID DERIVATIVE

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.

PYRROLIDIN-3-YLACETIC ACID DERIVATIVE

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.